Header
Header
Article

Keytruda Granted Accelerated Approval for Treatment of HCC



The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor accelerated approval for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib.

Source link

Back to top button